AL-DAWAA MEDICAL SERVICES COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.8 SAR | -1.63% |
|
-3.40% | -14.18% |
| Apr. 30 | Aldawaa Medical Services Posts Higher Q1 Net Profit, Revenue | MT |
| Apr. 30 | Al-Dawaa Medical Services Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,112 | 8,993 | 7,718 | - | - |
| Enterprise Value (EV) 1 | 6,112 | 11,093 | 9,164 | 8,654 | 8,576 |
| P/E ratio | 20 x | 27.3 x | 19.3 x | 16.3 x | 14.7 x |
| Yield | - | - | 3.19% | 3.62% | 4.41% |
| Capitalization / Revenue | 1.14 x | 1.57 x | 1.24 x | 1.17 x | 1.09 x |
| EV / Revenue | 1.14 x | 1.93 x | 1.47 x | 1.31 x | 1.21 x |
| EV / EBITDA | 8.45 x | 13.4 x | 9.99 x | 8.84 x | 8.3 x |
| EV / FCF | - | 21.8 x | 15.3 x | 17.4 x | 17.5 x |
| FCF Yield | - | 4.59% | 6.54% | 5.75% | 5.71% |
| Price to Book | - | 6.85 x | 5.53 x | 4.94 x | 4.55 x |
| Nbr of stocks (in thousands) | 85,000 | 85,000 | 85,000 | - | - |
| Reference price 2 | 71.90 | 105.8 | 90.80 | 90.80 | 90.80 |
| Announcement Date | 3/26/23 | 3/18/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 5,034 | 5,372 | 5,741 | 6,228 | 6,619 | 7,085 |
| EBITDA 1 | - | 600.1 | 723.6 | 830.4 | 917.2 | 979.2 | 1,033 |
| EBIT 1 | - | 266.2 | 369 | 466.7 | 536.6 | 571.6 | 623.2 |
| Operating Margin | - | 5.29% | 6.87% | 8.13% | 8.62% | 8.64% | 8.8% |
| Earnings before Tax (EBT) 1 | - | 246 | - | 342.4 | 412 | 500.3 | 545.5 |
| Net income 1 | 246.4 | 239.1 | 305.4 | 329.2 | 399.7 | 474.7 | 524.6 |
| Net margin | - | 4.75% | 5.69% | 5.73% | 6.42% | 7.17% | 7.41% |
| EPS 2 | 1,232 | 2.810 | 3.590 | 3.870 | 4.702 | 5.581 | 6.170 |
| Free Cash Flow 1 | - | 291.7 | - | 508.9 | 599 | 498 | 490 |
| FCF margin | - | 5.79% | - | 8.86% | 9.62% | 7.52% | 6.92% |
| FCF Conversion (EBITDA) | - | 48.6% | - | 61.28% | 65.3% | 50.86% | 47.42% |
| FCF Conversion (Net income) | - | 121.96% | - | 154.58% | 149.85% | 104.92% | 93.4% |
| Dividend per Share 2 | - | 4.130 | - | - | 2.898 | 3.285 | 4.001 |
| Announcement Date | 12/22/21 | 3/31/22 | 3/26/23 | 3/18/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|
| Net sales 1 | - | 1,439 | 1,458 | 1,516 |
| EBITDA | - | - | 215.6 | - |
| EBIT 1 | - | 102 | 127.7 | 130.5 |
| Operating Margin | - | 7.09% | 8.76% | 8.61% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income 1 | 89.33 | 71.28 | 92.35 | 95.33 |
| Net margin | - | 4.95% | 6.33% | 6.29% |
| EPS | 1.050 | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/3/23 | 11/2/23 | 3/18/24 | 4/29/24 |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 2,100 | 1,446 | 936 | 858 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 2.528 x | 1.577 x | 0.9561 x | 0.8304 x |
| Free Cash Flow 1 | - | 292 | - | 509 | 599 | 498 | 490 |
| ROE (net income / shareholders' equity) | - | 22.8% | - | 27.3% | 29.4% | 30.7% | 31% |
| ROA (Net income/ Total Assets) | - | 6.31% | - | 7.15% | 8.32% | 9.49% | 9.49% |
| Assets 1 | - | 3,788 | - | 4,602 | 4,802 | 5,004 | 5,528 |
| Book Value Per Share 2 | - | 11.60 | - | 15.40 | 16.40 | 18.40 | 20.00 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 378 | - | 217 | 223 | 235 | 225 |
| Capex / Sales | - | 7.52% | - | 3.78% | 3.58% | 3.55% | 3.18% |
| Announcement Date | 12/22/21 | 3/31/22 | 3/26/23 | 3/18/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
90.8
SAR
Average target price
114.2
SAR
Spread / Average Target
+25.74%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.18% | 2.06B | |
| -29.72% | 15.82B | |
| -22.51% | 12.65B | |
| -22.88% | 6.6B | |
| +12.34% | 6.3B | |
| -6.01% | 6.11B | |
| +64.02% | 4.75B | |
| -1.17% | 4.69B | |
| -5.50% | 4.02B | |
| -8.59% | 3.59B |
- Stock Market
- Equities
- 4163 Stock
- Financials Al-Dawaa Medical Services Company
